GlassScriptPhysician profile
Renee Moos
NPI 1083066328
$3,666.17
in general payments reported to CMS, 2019-2025
19 companies · $777 in 2025
The $777 reported for 2025 was more than what 95% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $720 · 2022: $833 · 2023: $863 · 2024: $474 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $396 · Consulting Fee: $88.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,628.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $396.00 |
| Consulting Fee | $88.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $978.42 | 2022-2025 | |
| Genzyme Corporation | $376.19 | 2021-2024 | |
| Incyte Corporation | $252.75 | 2021-2023 | Jakafi |
| Servier Pharmaceuticals LLC | $248.44 | 2022-2023 | |
| Sobi, INC | $224.00 | 2021-2023 | |
| Apellis Pharmaceuticals, INC. | $208.72 | 2021-2024 | Empaveli |
| Octapharma USA, INC. | $148.75 | 2021-2024 | Nuwiq, Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Uswm, LLC | $129.51 | 2025 | Iwilfin |
| Chiesi USA, INC. | $122.44 | 2023 | Ferriprox |
| Csl Behring | $122.21 | 2022 | |
| Day One Biopharmaceuticals | $120.29 | 2024 | Ojemda |
| Alexion Pharmaceuticals, INC. | $119.20 | 2025 | Koselugo |
| Amgen INC. | $118.40 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.77 | 2024 | |
| United Therapeutics Corporation | $113.92 | 2023 | Unituxin |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Y-Mabs Therapeutics, INC. | $100.99 | 2022 | |
| Spark Therapeutics, INC. | $77.34 | 2021 | |
| Pfizer INC. | $67.35 | 2023 | |
| Kedrion Biopharma, INC. | $19.48 | 2025 | Kedrab, Gammaked, Koate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Moos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.